For Medical Professionals
How does the referral process work for the BMT program?
We welcome referrals of your patients at any time. To begin the referral process, please contact us with the following information available:
- Diagnosis and status of disease.
- Demographic information, including insurance information.
- A brief, one-page medical summary outlining your medical status and clinical treatment course.
- Insurance information.
While a referral by a physician to our program will speed the process, patients interested in our program are encouraged to contact us directly.
University of Minnesota Masonic Children's Hospital
BMT Referral & Consultation / The Blood and Marrow Transplant Program
Tel: 612-273-2800 or (toll-free) 888-601-0787 Fax: 612-273-2919
Page the pediatric BMT attending physician on-call 24-hours-a day at 612-365-1000.
BMT Educational Presentations for Medical Staff
If you are interested in having a BMT physician visit your clinic or hospital to talk about pediatric BMT, whether in a Grand Rounds format or visit, please contact Todd Koehler at firstname.lastname@example.org to discuss opportunities.
Our fellowship program provides clinical and research training experience of exceptional breadth and depth in blood and marrow transplantation. Facts about our Fellowship Program:
Accredited/Nonaccredited: Not applicable (no accreditation available for Bone & Marrow Transplantation Pediatric fellowships currently)
Overview of General Schedule: BMT fellow will spend 9 months among the BMT inpatient and outpatient services with the remaining 3 months spent participating in research activities with BMT faculty
Funding: NIH training grant, private funding, affiliate funding
Strengths of program:
- Nationally/internationally recognized clinical and basic science investigators providing fellows with exposure to a wide variety of diseases but also multiple conditioning regimens and bone marrow sources including double and triple umbilical cord blood transplants
- One of the largest blood and marrow transplant programs in the United States with national and international referrals.
- The University of Minnesota Cancer Center, one of only thirty-five NCI designated Comprehensive Cancer Centers in the United States.
Types of research fellows could pursue (e.g. lab, clinical, community-based, etc.):
It is the belief of all members of the section that basic biological and clinical research is as important in Pediatric BMT as is the care of those children in the clinic. The fellowship seeks to train clinicians in such a manner that they are able to propose and answer scientific questions, which might not be obvious to either the basic scientist or clinician alone. Thus, the integration of clinical science and basic laboratory science are of vital importance to this training program. To this end, fellows are supported in the further development of research skills established during their prior training in Pediatric Hematology/Oncology. Their research in a focused area, in the future, throughout his or her research career, contribute to the continued advancement of the BMT field as a whole.
For more information, please contact:
Dr. Angie Smith
Coming soon: New trial to reduce immunosuppression in Fanconi Anemia patients following transplant
Fanconi anemia (FA) is a rare, genetically and phenotypically heterogeneous, inherited disorder that affects roughly 1 in 130,000 people worldwide. At University of Minnesota Masonic Children's Hospital, we care for more patients with FA than anywhere else in the US. Typically diagnosed in childhood, FA is characterized by congenital abnormalities, bone marrow failure and a propensity to develop malignancies. Allogeneic hematopoietic cell transplant (HCT) is the only curative option presently available for the hematological manifestations of FA. Significant advances in this field have allowed for dramatic improvements in patient survival after HCT. Achievement of successful transplantation largely hinges on striking a delicate balance between immune suppression, which allows transplanted cells to take and grow, and immune surveillance, necessary for protecting against potentially lethal infections. Read more.
New reduced-intensity, pre-transplant conditioning regimen makes transplant a reality for patients with Dyskeratosis congenita
Dyskeratosis congenita (DC) is a rare, genetically and clinically heterogeneous, inherited disorder affecting one in every million persons worldwide. While bone marrow failure (BMF) is the primary cause of premature mortality, additional clinical complications include pulmonary fibrosis, liver disease, mucocutaneous abnormalities, and cancer. Physician-researchers at University of Minnesota Masonic Children's Hospital developed a reduced-intensity conditioning regimen that, unlike traditional approaches, only partially ablates endogenous bone marrow cells, allowing for more rapid recovery, fewer toxicities, and reduced risk of infection. Learn more.
New results show similar outcomes for Fanconi anemia patients, regardless of stem cell source
Historically, outcomes after HLA matched sibling donor transplant for Fanconi anemia (FA) have been superior to those observed after alternative donor (AD) (i.e., unrelated or HLA mismatched related donor) transplant. Alternative transplantation has most often been complicated by high rates of graft failure, graft-versus-host-disease (GVHD), organ toxicity and infection, resulting in poor survival rates. Over the past two decades, our transplant approach has been modified, leading to marked improvements in outcomes. Learn more.
Building on the Past - Looking to the Future
While newborn screening programs vary from state to state, many are expanding their screening programs to test for diseases such as ALD and Hurler syndrome. Learning that their newborn has tested positive for a rare disease is devastating and confusing for parents. The Inherited Metabolic Disorder Comprehensive Care Program at University of Minnesota Masonic Children's Hospital is available to these families, as well as to families with a child diagnosed later in the disease process. Read More.